WO2014073447A1 - カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 - Google Patents
カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 Download PDFInfo
- Publication number
- WO2014073447A1 WO2014073447A1 PCT/JP2013/079551 JP2013079551W WO2014073447A1 WO 2014073447 A1 WO2014073447 A1 WO 2014073447A1 JP 2013079551 W JP2013079551 W JP 2013079551W WO 2014073447 A1 WO2014073447 A1 WO 2014073447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- polymer compound
- ratio
- compound according
- Prior art date
Links
- 0 CC(CC(**)=O)CN(C)C Chemical compound CC(CC(**)=O)CN(C)C 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a polymer compound in which camptothecins and an anticancer (antitumor) effect enhancer are bound to the same molecule.
- the polymer compound described herein can be used for the purpose of delivering various types of drugs to the affected area.
- Camptothecin is a plant alkaloid extracted from the Chinese plant "Yuki” and is a type I topoisomerase inhibitor. This selectively binds to type I topoisomerase complexed with DNA and stabilizes its structure. As a result, the cleaved DNA cannot be recombined, and is a drug that induces cell death by stopping DNA synthesis. Camptothecin showed a high antitumor effect and was developed as an anticancer drug in the 1960s. However, clinical trials were canceled due to myelosuppression and hemorrhagic cystitis as strong toxicity.
- topotecan and irinotecan were developed as derivatives that are more soluble in water than camptothecin and have stronger antitumor activity but lower toxicity.
- Topotecan exerts an antitumor effect without undergoing metabolism, and side effects of diarrhea are mild because 20-40% of the dose is renal excretion.
- irinotecan itself has an antitumor effect, it is metabolized in vivo by carboxylesterase to an active metabolite, 7-ethyl-10-hydroxycamptothecin (hereinafter referred to as EHC), and has a stronger antitumor effect. Demonstrate.
- irinotecan and EHC are characterized in that they are present in plasma as a lactone type that is more biologically active than topotecan and have a longer half-life.
- camptothecin derivatives are used in many cancer types.
- Topotecan has been approved for use in small cell lung cancer and ovarian cancer that has been pre-treated with cancer chemotherapeutic agents.
- irinotecan is small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, gastric cancer (inoperable or recurrent), colorectal cancer (inoperable or recurrent), breast cancer (inoperable or recurrent), spiny cells. Approved with broad indications for cancer and malignant lymphoma (non-Hodgkin lymphoma).
- Patent Document 1 discloses a polymerized camptothecin derivative.
- This polymer conjugate is obtained by esterifying phenolic camptothecins to a copolymer of polyethylene glycols and a polymer having a carboxy group in the side chain.
- the polymer conjugate is a camptothecin derivative that has sustained release in vivo and has an excellent therapeutic effect by binding camptothecins with a phenyl ester bond that is easily chemically cleaved.
- the polymer conjugate is expected to form micelles and selectively have a medicinal effect on tumors with few side effects.
- it is considered that the ability to release camptothecins independent of enzymes is unlikely to be affected by individual differences in patients in terms of therapeutic effect.
- PARP Poly (ADP-ribose) polymerase
- oxidized NAD nicotinamide adenine dinucleotide
- PARP inhibitor competitively inhibits oxidized NAD and exerts a pharmacological action. That is, by inhibiting PARP, the DNA single-strand breakage of the tumor cell causes a double-strand DNA breakage that is further important for cell survival, resulting in the death of the tumor cell.
- BRCA (Breast Cancer Susceptibility Gene) mutant breast cancer which is representative of hereditary breast cancer, exerts an antitumor effect by inhibiting PARP acting in the complementary pathway of the DNA repair pathway.
- PARP Breast Cancer Susceptibility Gene
- PARP plays an important role in the recognition and repair of DNA damage, its inhibitor is presumed to be an effect enhancer of anticancer drugs having DNA damage action, and it is effective when combined with anticancer drugs such as temozolomide, carboplatin, and gemcitabine. In anticipation of this possibility, development of cancer treatment using PARP inhibitors is currently underway.
- BRCA1 or BRCA2 mutation-positive tumors have been successfully treated with other anticancer agents (carboplatin, gemcitabine, etc.), and favorable results have been shown.
- a PARP inhibitor rucaparib derivative is treated with cancer in combination with temozolomide, and is well tolerated and has good anticancer effects.
- Patent Document 1 reports a polymer compound in which one kind of drug having a phenolic hydroxyl group is bound
- Patent Document 2 reports a polymer compound in which one kind of drug having an alcoholic hydroxyl group is bound
- Patent Document 3 and Non-Patent Document 1 report a combined administration of a low molecular weight anticancer agent such as temozolomide, carboplatin, and gemcitabine and a PARP inhibitor, or a polymer compound in which doxorubicin is combined with another anticancer agent.
- a polymer compound in which camptothecins and an anticancer effect enhancer such as a PARP inhibitor are bound to the same molecule is not known.
- the object of the present invention is to provide a high molecular compound in which camptothecins and an anticancer effect enhancer, particularly a PARP inhibitor, are bonded to the same molecule, so that the toxicity to normal cells is low, and two agents are efficiently applied to the affected area. By delivering and releasing, the drug efficacy is improved.
- the present inventors have created a polymer compound in which camptothecins and an anti-cancer effect enhancer, particularly a PARP inhibitor, are bound to the same molecule, and the compound can provide a satisfactory therapeutic effect as a chemotherapeutic agent.
- the present invention has been achieved. That is, the gist of the present invention is the following configurations 1) -12).
- a polymer compound represented by the following general formula (1) [Wherein R 1 represents an optionally substituted (C1-C4) alkyl group, t represents an integer of 45-450, A represents a (C1-C6) alkylene group, and d + e + f + g + h represents Represents an integer of 6-60, the ratio of d to d + e + f + g + h is 5-50%, the ratio of e is 5-90%, the ratio of f is 0-90%, the ratio of g is 0-90%, the ratio of h is 0 to 90%, R 2 represents a hydrogen atom or a (C1-C4) acyl group, R 3 represents an anticancer effect enhancer residue or an aspartic acid residue to which an anticancer effect enhancer is bound, 4 represents an aspartic acid residue and / or an aspartic imide residue, R 5 represents N (R 6 ) CONH (R 7 ), and R 6 and R 7 may be the same or different.
- R 1 is methyl group or ethyl group
- A is ethylene group or trimethylene group
- R 2 is acetyl group or propionyl group
- R 6 and R 7 are both cyclohexyl group or isopropyl group
- the ratio of d to d + e + f + g + h is 5
- the polymer compound according to 1) wherein -40%, e ratio is 5-80%, f ratio is 0-60%, g ratio is 5-40%, and h ratio is 0-30%. .
- R 3 is the following general formula (2) or general formula (3).
- R 8 and R 9 each independently represents a hydrogen atom or a (C1-C6) alkyl group optionally having substituent (s), and R 10 may have a hydrogen atom or substituent (s).
- a good (C1-C40) alkyl group, an optionally substituted (C1-C40) aralkyl group, an optionally substituted aromatic group or carboxy group represents an amino acid residue protected.
- CX-CY represents CH—CH or C ⁇ C (double bond)
- OD (O represents an oxygen atom) represents an anticancer effect enhancer residue
- R 4 is a group selected from a substituent group consisting of the following general formula (4), general formula (5), and general formula (6).
- R 8 , R 9 , R 10 and CX-CY have the same meaning as described above, R 11 represents a hydroxyl group or N (R 12 ) CONH (R 13 ), and R 12 and R 13 are the same. May be different and represents a (C3-C6) branched or cyclic alkyl group or a (C1-C5) branched or straight chain alkyl group optionally substituted with a tertiary amino group]
- the PARP inhibitor is 1H-benzimidazole-4-carboxamide derivative, olaparib derivative, lucaparib derivative, BMN673 (5-Fluoro-8 (S)-(4-fluorphenyl) -9 (R)-(1-methyl- 1H-1,2,4-triazol-5-yl) -3,7,8,9-tetrahydro-2H-pyrido [4,3,2-de] phthalazin-3-one) derivatives
- the PARP inhibitor is 2- (4-hydroxyphenyl) -1H-benzimidazole-4-carboxamide or 2- (4′-hydroxyphenyl) -3,4,5,6-tetrahydro-1H-azepino [5 , 4,3-cd] Indol-6-one, the polymer compound as described in 6), 7) or 9) above.
- the PARP inhibitor is 2- (4′-hydroxymethylphenyl) -3,4,5,6-tetrahydro-1H-azepino [5,4,3-cd] indol-6-one or 4- [4- 10.
- An anticancer agent comprising the polymer compound according to any one of 1) to 11) as a medicinal ingredient.
- the polymer compound of the present invention is characterized in that EHC, which is a camptothecin, which is a key drug in cancer chemotherapy, is bound to an anti-cancer effect enhancer, particularly a PARP inhibitor. It is a drug delivery system that can control the speed, and can simultaneously deliver drugs to the affected area, so that it can improve anticancer effect and reduce side effects, and achieve efficient and safe cancer chemotherapy be able to.
- the ratio of the released amount of EHC and PARP inhibitor (NU1085) at 37 ° C. in PBS solution of Compound 1 (phosphate buffered saline; pH 7.1) to the total amount of bound drug is shown.
- the ratio of the release amount of EHC and PARP inhibitor 2 at 37 ° C. in the PBS solution of Compound 2 (phosphate buffered saline; pH 7.1) with respect to the total amount of bound drug is shown.
- the ratio of the release amount of EHC and PARP inhibitor 3 at 37 ° C. in the PBS solution of Compound 7 (phosphate buffered saline; pH 7.1) with respect to the total amount of bound drug is shown.
- the polymer compound in which the camptothecins of the present invention and the anticancer effect potentiator are bonded to the same molecule is a block copolymer of a polyethylene glycol structural moiety and a polyglutamic acid structural moiety bound to a drug, etc.
- Formula (1) [wherein R 1 represents an optionally substituted (C1-C4) alkyl group, t represents an integer of 45-450, and A represents a (C1-C6) alkylene group.
- D + e + f + g + h represents an integer of 6-60, the ratio of d to d + e + f + g + h is 5-50%, the ratio of e is 5-90%, the ratio of f is 0-90%, the ratio of g is 0-90%, the percentage of h is 0-90%, R 2 represents a hydrogen atom or a (C1-C4) acyl group, and R 3 is an anti-cancer effect enhancer residue or an aspartic acid residue bound with an anti-cancer effect enhancer R 4 is asparagus Represents a formic acid residue and / or an aspartic acid imide residue, R 5 represents N (R 6 ) CONH (R 7 ), and R 6 and R 7 may be the same or different, and (C3-C6) A branched or cyclic alkyl group or a (C1-C5) branched or straight chain alkyl group optionally substituted with a tertiary amino group].
- the (C1-C4) alkyl group in R 1 of the general formula (1) is, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group or a tert-butyl group. It is.
- substituent of the (C1-C4) alkyl group which may have a substituent include an amino group, a dialkylamino group, an alkyloxy group, and a carboxy group.
- R 1 is preferably a methyl group or an ethyl group, and particularly preferably a methyl group.
- T in the general formula (1) is 45-450, preferably 90-340.
- Examples of A in the general formula (1) which is a linking group that connects a polyethylene glycol structural part and a polyglutamic acid structural part include (C1-C6) alkylene groups such as methylene group, ethylene group, trimethylene group, tetramethylene group. Group, hexamethylene group and the like. Among them, an ethylene group or a trimethylene group is preferable, and a trimethylene group is particularly preferable.
- the polyglutamic acid structure portion of the polymer compound of the present invention represented by the general formula (1) is a structure in which glutamic acid units are bonded in an ⁇ -amino acid type, and each glutamic acid unit may be L-type or D-type.
- the total number of glutamic acid units d + e + f + g + h in the general formula (1) is 6-60, preferably 8-40. Therefore, the average molecular weight of the polyglutamic acid structure portion is about 600-15000, preferably about 800-10000.
- R 2 in the general formula (1) includes a hydrogen atom or a (C1-C4) acyl group.
- R 2 is preferably a (C1-C4) acyl group, for example, a formyl group, an acetyl group, a propionyl group, etc. Among them, an acetyl group or a propionyl group is preferable, and an acetyl group is particularly preferable.
- R 5 in the general formula (1) is N (R 6 ) CONH (R 7 ), and R 6 and R 7 may be the same or different, and (C3-C6) branched or cyclic alkyl group or tertiary amino group (C1-C5) branched or straight chain alkyl group optionally substituted by a group.
- Examples of the (C3-C6) branched or cyclic alkyl group include isopropyl group, isobutyl group, sec-butyl group, tert-butyl group, 1-methylbutyl group, 2-methylbutyl group, neopentyl group, cyclohexyl group and the like. More preferred are isopropyl group and cyclohexyl group.
- Examples of the (C1-C5) branched or straight chain alkyl group optionally substituted with a tertiary amino group include an ethyl group and a dimethylaminopropyl group.
- EHC which is a camptothecin
- EHC has an ester bond at its 10-position hydroxyl group with a side chain carboxy group of polyglutamic acid.
- R 3 in the general formula (1) is an anticancer effect enhancer residue or an aspartic acid residue to which an anticancer effect enhancer is bound.
- the anticancer effect enhancer is a drug administered mainly for enhancing the effect of an anticancer agent by various action mechanisms, and examples thereof include PARP inhibitors and flavonoid derivatives.
- the PARP inhibitor examples include 1H-benzimidazole-4-carboxamide derivatives, olaparib derivatives, lucaparib derivatives, veripalib derivatives, iniparib derivatives, niaparib derivatives, BMN673 (5-Fluoro-8 (S) )-(4-fluorophenyl) -9 (R)-(1-methyl-1H-1,2,4-triazol-5-yl) -3,7,8,9-tetrahydro-2H-pyrido [4,3 , 2-de] phthalazin-3-one) derivatives, E7016-related compounds, and the like.
- the compound serving as a substituent for R 3 may be single or plural in one molecule or between molecules, but is preferably a single compound.
- the anticancer effect enhancer has a phenolic hydroxyl group in the molecule
- the phenolic hydroxyl group and the side chain carboxy group of the polyglutamic acid structure portion of the block copolymer may be bonded by an ester bond.
- the anticancer effect enhancer has a phenolic hydroxyl group in the molecule or a primary or secondary alcoholic hydroxyl group in the molecule
- the hydroxyl group and the side chain carboxy group of the polyglutamic acid structure portion of the block copolymer are combined with asparagine.
- An acid derivative may be bound as a linker.
- the hydroxyl group of the anti-cancer effect enhancer and the carboxy group of the aspartic acid derivative are ester-bonded, the remaining carboxy group is amidated, and the amino group of the resulting compound and the side chain carboxy of the polyglutamic acid structure portion of the block copolymer
- the group may be bonded by an amide bond.
- Examples of the PARP inhibitor to be bound to the polymer compound of the present invention include compounds represented by the following formulas (7) to (17).
- 2- (4-hydroxyphenyl) -1H-benzimidazole-4-carboxamide (NU1085) represented by the formula (7) is preferably used.
- the compound represented by the formula (7) is a compound known per se. Med. Chem. , 43, 4084 (2000).
- the compounds represented by formula (8) and formula (9) are known compounds. Med. Chem. , 51, 6581 (2008).
- the compounds represented by the formula (10) to the formula (14) are known compounds and can be produced, for example, according to the description in International Publication No. 2000/042040.
- the compounds represented by the formula (15) to the formula (17) are known compounds and can be produced, for example, according to the description in WO2010 / 017055.
- Examples of the residue of the compound obtained by ester-linking the hydroxyl group of the anticancer effect enhancer and the carboxy group of the aspartic acid derivative used as a linker include, for example, the general formula (2) or the general formula (3) [wherein R 8, R 9 each independently represents a hydrogen atom or a (C1-C6) alkyl, R 10 is a hydrogen atom, which may have a substituent (C1-C40) alkyl group, have a substituent An optionally substituted (C1-C40) aralkyl group, an optionally substituted aromatic group or a carboxy group, and CX-CY represents CH—CH or C ⁇ C ( Double bond), and OD (O represents an oxygen atom) represents an anticancer effect potentiator residue].
- R 8, R 9 each independently represents a hydrogen atom or a (C1-C6) alkyl
- R 10 is a hydrogen atom, which may have a substituent (C1-C40) alkyl group, have a substituent
- the aspartic acid derivative used as a linker in the present invention includes a group represented by the above general formula (2) or general formula (3) in which CX-CY is C ⁇ C (double bond).
- CX-CY is C ⁇ C (double bond)
- the E configuration is preferable.
- HOD represents an anticancer effect enhancer.
- Examples of the (C1-C6) alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an s-butyl group, an isobutyl group, an n-pentyl group, and an n-hexyl group.
- Etc. R 8 and R 9 are preferably hydrogen atoms.
- Examples of the (C1-C40) alkyl group in the optionally substituted (C1-C40) alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, s-butyl group, isobutyl group, n-pentyl group, n-hexyl group, n-stearyl group and the like.
- Examples of the substituent include phenyl group, naphthyl group, benzyl group, methoxy group, ethoxy group, A dimethylamino group etc. are mentioned.
- Examples of the (C1-C40) aralkyl group in the optionally substituted (C1-C40) aralkyl group include a benzyl group, a naphthylmethyl group, a phenethyl group, a 4-phenylbutyl group, and the like.
- Examples of the group include a methyl group, an ethyl group, a nitro group, a chlorine atom, a bromine atom, and a dimethylamino group.
- Examples of the aromatic group which may have a substituent include groups derived from aniline, nitroaniline, chloroaniline, aminofluorobenzonitrile, aminonaphthalene, aminoflavone, aminofluorene and the like.
- the substitution position of the substituent in each group is not particularly limited as long as substitution is possible, and the number of substitutions is not particularly limited.
- amino acid of the amino acid residue in which the carboxy group is protected examples include amino acids in which the carboxy group used in normal peptide synthesis is protected, and a compound in which the carboxy group of the amino acid is protected with an ester or an amide is preferable.
- Examples of the compound protected with an ester include (C1-C12) alkyl ester optionally having an amino acid substituent, that is, (C1-C12) alkyl ester of alanine, ⁇ or ⁇ ( C1-C12) alkyl ester, ⁇ or ⁇ (C1-C12) alkyl ester of glutamic acid, (C1-C12) alkyl ester of phenylalanine, (C1-C12) alkyl ester of cysteine, (C1-C12) alkyl ester of glycine, Mouth Ishin (C1 C12) Alkyl ester, (C1-C12) alkyl ester of isocynine, (C1-C12) alkyl ester of histidine, (C1-C12) alkyl ester of pufflin, (C1-C12) alkyl ester of serine, threonine (C1-C12) alkyl ester of va
- Examples of the sugar of the sugar residue that may have a substituent include glucosamine, galactosamine, mannosamine and the like, and examples of the substituent include an acetyl group, a pivaguchiyl group, a benzyl group, and a methyl group. It is done.
- the sugar may be D-form, L-form, or a mixture thereof.
- the substitution position and the number of substitutions of the substituent are not particularly limited as long as they are possible.
- R 10 is particularly preferably an n-butyl group, a phenylbutyl group, etc. Among them, a phenylbutyl group is particularly preferable.
- CX-CY is preferably CH-CH.
- R 4 in the general formula (1) is an aspartic acid residue and / or an aspartic imide residue.
- the general formula (4), the general formula (5), and the general formula (6) [wherein R 8 , R 9 , R 10 and CX-CY have the same meaning as described above, R 11 represents a hydroxyl group or N (R 12 ) CONH (R 13 ), and R 12 and R 13 may be the same or different, A group selected from the substituent group consisting of (C3-C6) a branched or cyclic alkyl group or a (C1-C5) branched or straight chain alkyl group optionally substituted with a tertiary amino group] is preferred. When these groups are present in the polymer compound, these groups may be mixed.
- R 8, R 9, R 10 , CX-CY is the same as R 8, R 9, R 10 , CX-CY in the R 3, it is the same preferable groups.
- the (C3-C6) branched or cyclic alkyl group includes, for example, isopropyl group, isobutyl group, sec-butyl group, tert-butyl group, 1-methylbutyl group, 2-methylbutyl group, neopentyl Group, cyclohexyl group, etc., more preferably isopropyl group, cyclohexyl group, etc.
- (C1-C5) branched or straight chain alkyl group optionally substituted by the tertiary amino group includes, for example, , Ethyl group, dimethylaminopropyl group and the like.
- a glutamic acid moiety may be present in the polyglutamic acid structure portion in the general formula (1), and in the general formula (1), a free acid form may be present, but an alkali metal salt or an alkaline earth metal salt may be used. These are also included in the present invention.
- the alkali metal salt or alkaline earth metal salt include lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt and the like.
- it when it is provided parenterally as an anticancer agent, it is prepared as a solution in a solution, but it may be a glutamate based on a salt of the pH buffer of the solution with a cation.
- a glutamic acid unit (the number of units is d) in which the camptothecin derivative (EHC) is bonded to a side chain carboxy group, and a glutamic acid unit in which the R 3 is bonded to a side chain carboxy group (The number of units is e), a glutamic acid unit in which R 4 is bonded to the side chain carboxy group (number of units is f), and a glutamic acid unit in which the R 5 is bonded to the side chain carboxy group (number of units).
- the side chain carboxy group may have a glutamic acid unit (the number of units is h) which is a free carboxy group or a salt thereof, and each may independently exist in a random arrangement.
- the total number of glutamic acid units in the polyglutamic acid structure portion of the block copolymer represented by the general formula (1) is represented by d + e + f + g + h, and the ratio of d is 5-50%, preferably 5-40%, and the ratio of e is 5-5.
- the polymer compound of the present invention may form a micelle having a polyethylene glycol structure portion as an outer shell and a polyglutamic acid structure portion to which a drug or the like is bound as an inner shell in water.
- the manufacturing method of the high molecular compound of this invention is not limited to the manufacturing method described here, and the method as described in an Example and a reference example of a postscript.
- the method for constructing the main chain of a block copolymer having a polyethylene glycol structural part and a polyglutamic acid structural part which is a polymer compound of the present invention represented by the general formula (1), comprises a polyethylene glycol structural part and a polyglutamic acid structural part. Any of a method of bonding and a method of sequentially polymerizing glutamic acid to the polyethylene glycol structure portion may be used.
- N-carbonylglutamic anhydride is added to polyethylene glycol modified with a methyl group at one end and an aminopropyl group at the other end.
- the method of reacting a thing sequentially is mentioned.
- the N-carbonylglutamic acid anhydride is preferably a compound in which the carboxy group of the glutamic acid side chain is modified with an appropriate carboxylic acid protecting group.
- the carboxylic acid protecting group is not particularly limited, but an ester type protecting group is preferable, and a benzyl ester is particularly preferable.
- the desired block copolymer is obtained by deprotection by an alkali hydrolysis reaction or a hydrogenolysis reaction.
- the terminal amino group of the polyglutamic acid structure portion of the block copolymer may be acylated.
- the block copolymer having the polyethylene glycol structural part and the polyglutamic acid structural part is bound with an aspartic acid derivative to which EHC, an anticancer effect enhancer or an anticancer effect enhancer is bound.
- the binding method is not particularly limited, and it may be possible to bind EHC first and then bind the anti-cancer effect enhancer or the aspartic acid derivative to which the anti-cancer effect enhancer is bound, in the reverse order, You may combine simultaneously.
- An example of a method for producing an aspartic acid derivative bound with an anticancer effect enhancer will be described later.
- a block copolymer having a polyethylene glycol structure part and a polyglutamic acid structure part, EHC, and an aspartic acid derivative to which an anticancer effect enhancer or an anticancer effect enhancer is bound in the presence of a carbodiimide dehydration condensing agent.
- a dehydration condensation reaction may be performed.
- an N (R 6 ) CONH (R 7 ) group can be simultaneously introduced into the block copolymer.
- carbodiimide dehydrating condensing agent examples include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPCI), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC) and the like.
- a reaction aid such as N, N-dimethylaminopyridine (DMAP) may be used.
- N (R 12 ) CONH (R 13 ) may be introduced into R 11 when binding the aspartic acid derivative to which the anticancer effect enhancer is bound.
- the polymer compound of the present invention can be produced via an optional purification step.
- the polymer compound of the present invention gradually dissociates and releases the anti-tumor active ingredient EHC and the anti-cancer effect enhancer in a phosphate buffered saline (PBS) solution. This indicates that even when administered in vivo, it has physical properties to release EHC and the anticancer effect enhancer gradually.
- the high molecular compound of this invention can set freely the coupling
- the high molecular compound of the present invention is different from low molecular weight drugs in terms of drug efficacy characteristics and side effect expression characteristics, and can provide a new therapeutic method using a camptothecin derivative and an anticancer effect enhancer. .
- the polymer compound of the present invention can be used as an anticancer agent, and the use of the anticancer agent is also included in the present invention.
- the anticancer agent can be used in commonly used preparations such as injections, drops, tablets, capsules, powders and the like.
- commonly used pharmaceutically acceptable carriers and additives such as binders, lubricants, disintegrants, solvents, excipients, solubilizers, dispersants, stabilizers, suspensions Agents, preservatives, soothing agents, pigments, fragrances and the like can be used. Among them, it is preferably used as an injection or a drip infusion.
- Water physiological saline, 5% glucose or mannitol solution, water-soluble organic solvent (for example, glycerol, ethanol, dimethyl sulfoxide, N-methylpyrrolidone, polyethylene glycol, cremophor, etc. And a mixture thereof, and a mixture of water and the water-soluble organic solvent are preferred.
- water-soluble organic solvent for example, glycerol, ethanol, dimethyl sulfoxide, N-methylpyrrolidone, polyethylene glycol, cremophor, etc. And a mixture thereof, and a mixture of water and the water-soluble organic solvent are preferred.
- the dose of the polymer compound is appropriately set in consideration of the patient's sex, age, physique, physiological condition, disease state, therapeutic effect, and the like.
- the dose per body surface area of a patient in terms of EHC as an active ingredient parenterally per day for an adult is 0.01-500 mg / m 2 , preferably 1-200 mg / m 2 .
- the polymer compound of the present invention makes it possible to enhance the therapeutic effect of a camptothecin derivative and is suitable for breast cancer, ovarian cancer, lung cancer, thyroid cancer, myeloid leukemia, hepatoblastoma, colon cancer, gallbladder cancer, etc. Is possible. In particular, a high therapeutic effect can be expected in chemotherapy of various cancers pretreated with a camptothecin derivative.
- the present invention will be further described below with reference to examples. However, the present invention is not limited to these examples.
- the present invention products Gaussian distribution analysis showing the size of the particles constituting in aqueous solution (particle size) were performed at Zeta Potential / Particlesizer NICOMP TM 380ZLS ( Particle Sizing Systems , Inc.).
- the content of EHC and NU1085 bound to Compound 1 was analyzed by HPLC (high performance liquid chromatography) after adding 1N sodium hydroxide aqueous solution to Compound 1 and stirring for 1 hour at 37 ° C. And calculated from the amount obtained from the calibration curve obtained with EHC and NU1085. As a result, the contents of bound EHC and NU1085 were 10.4% (w / w) and 10.2% (w / w), respectively.
- the reaction solution was slowly added dropwise to a mixed solution of 10 ml of ethanol, 3 ml of ethyl acetate and 80 ml of diisopropyl ether and stirred at room temperature for 1 hour, and the precipitate was collected by filtration to obtain ethanol / diisopropyl ether (1/4 (v / v)). Washed with.
- the obtained precipitate was dissolved in 37 ml of acetonitrile and 3.7 ml of water, an ion exchange resin (Dow Chemical Dowex 50 (H + ), 3.7 ml) was added, and the mixture was stirred and filtered. Acetonitrile in the obtained filtrate was distilled off under reduced pressure, and then lyophilized to obtain Compound 2 (513 mg).
- the content of EHC and PARP inhibitor 2 bound to compound 2 was determined by adding 1N sodium hydroxide aqueous solution to compound 2 and stirring at 37 ° C. for 1 hour, and then separating the released EHC and PARP inhibitor 2 by HPLC (high performance liquid chromatography). ) And calculated from the amount obtained from the calibration curve obtained with EHC and PARP inhibitor 2. As a result, the contents of bound EHC and PARP inhibitor 2 were 10.8% (w / w) and 9.6% (w / w), respectively.
- Synthesis Example 2 Synthesis of N- (tert-butoxycarbonyl) aspartic acid-1-phenylbutyramide (Compound 4) 7.2 g of Compound 3 obtained in Synthesis Example 1 was dissolved in 30 ml of ethyl acetate, and 5% palladium carbon After adding 2.8 g (water content 50%), the inside of the system was replaced with hydrogen and stirred overnight at room temperature in a hydrogen atmosphere. 5% Palladium carbon was filtered and washed with ethyl acetate. The filtrate and the washing solution were combined, and the ethyl acetate was distilled off under reduced pressure, followed by vacuum drying to obtain 5.4 g of Compound 4.
- the reaction solution was slowly added dropwise to a mixed solution of 15 ml of ethanol, 15 ml of ethyl acetate, and 120 ml of diisopropyl ether, stirred at room temperature for 1 hour, and the precipitate was collected by filtration to obtain ethanol / diisopropyl ether (1/4 (v / v)). Washed with.
- the obtained precipitate was dissolved in 38 ml of acetonitrile and 3.8 ml of water, ion exchange resin (Dow Chemical Dowex 50 (H + ), 7.6 ml) was added, and the mixture was stirred and filtered. Acetonitrile in the obtained filtrate was distilled off under reduced pressure, and then freeze-dried to obtain 510 mg of compound 7.
- the content of EHC and PARP inhibitor 3 bound to compound 7 was determined by adding 1N sodium hydroxide aqueous solution to compound 7 and stirring at 37 ° C. for 1 hour, and then separating the released EHC and PARP inhibitor 3 by HPLC (high performance liquid chromatography). ) And calculated from the amount obtained from the calibration curve obtained with EHC and PARP inhibitor 3. As a result, the contents of bound EHC and PARP inhibitor 3 were 12.0% (w / w) and 7.1% (w / w), respectively.
- Example 4 Polymer compound in which EHC and Compound 9 are combined (Compound 10) 518 mg of the methoxypolyethylene glycol-polyglutamic acid block copolymer described in Example 1 prepared by a method according to the method described in the pamphlet of International Publication No. 2006/120914 is dissolved in 8.0 ml of DMF and stirred at 35 ° C. for 15 minutes. Then, the mixture was stirred at 25 ° C. for 1 hour. Thereafter, 100 mg of EHC, 60 ⁇ l of DIPCI, and 9.4 mg of DMAP were added, and the mixture was stirred at 25 ° C. for 6 hours.
- the content of EHC and PARP inhibitor 4 bound to compound 10 was determined by adding 1N sodium hydroxide aqueous solution to compound 10 and stirring at 37 ° C. for 1 hour, and then separating the released EHC and PARP inhibitor 4 by HPLC (high performance liquid chromatography). ) And calculated from the amount obtained from the calibration curve obtained with EHC and PARP inhibitor 4. As a result, the contents of bound EHC and PARP inhibitor 4 were 11.3% (w / w) and 15.6% (w / w), respectively.
- the content of NU1085 bound to compound 11 was obtained by adding 1N-sodium hydroxide aqueous solution to compound 11 and stirring at 37 ° C. for 1 hour, and analyzing the released NU1085 by HPLC (high performance liquid chromatography). Calculated from the amount obtained from the calibration curve. As a result, the content of bound NU1085 was 14.6% (w / w).
- 2006/120914 pamphlet polyethylene glycol having a molecular weight of 5000 with one end having a methyl group and the other end having an aminopropyl group 620 mg EHC 100 mg and 100 mg of 2- (4-hydroxyphenyl) benzimidazole-1H-4-carboxamide (NU1085), having a structure part and a polyglutamic acid structure part (terminal acetyl group) having a polymerization number of 10
- the mixture was stirred at 20 ° C for 1 hour.
- 307 ⁇ l of DIPCI and 12 mg of DMAP were added and stirred at 20 ° C. for 18 hours.
- the content of EHC and NU1085 bound to Compound 12 was analyzed by HPLC (High Performance Liquid Chromatography) after adding 1N sodium hydroxide aqueous solution to Compound 1 and stirring at 37 ° C. for 1 hour. And calculated from the amount obtained from the calibration curve obtained with EHC and NU1085. As a result, the contents of bound EHC and NU1085 were 10.5% (w / w) and 12.0% (w / w), respectively.
- a Gaussian distribution analysis was performed using an aqueous solution of Compound 12 (1 mg / ml), and the result was 6 nm (volume weighting). Therefore, Compound 12 was considered to form micelles in water.
- Example 6 Polymer compound in which EHC and Compound 9 are combined (Compound 13) Methoxypolyethyleneglycol-polyglutamic acid block copolymer prepared by the method described in the pamphlet of International Publication No. 2006/120914 (polymerized with a polyethyleneglycol structure part having a molecular weight of 5000 and one end having a methyl group and the other end having an aminopropyl group) 164 mg of a block copolymer (terminal N acetyl group) composed of a polyglutamic acid structure part having a number of 10 was dissolved in 5.0 ml of DMF, stirred at 35 ° C. for 15 minutes, and then stirred at 25 ° C. for 1 hour.
- a block copolymer terminal N acetyl group
- the content of EHC and PARP inhibitor 4 bound to compound 13 was determined by adding 1N-sodium hydroxide aqueous solution to compound 13 and stirring at 37 ° C. for 1 hour, and then separating the released EHC and PARP inhibitor 4 by HPLC (high performance liquid chromatography). ) And calculated from the amount obtained from the calibration curve obtained with EHC and PARP inhibitor 4. As a result, the contents of bound EHC and PARP inhibitor 4 were 13.3% (w / w) and 11.8% (w / w), respectively.
- a Gaussian distribution analysis was performed using an aqueous solution of Compound 13 (1 mg / ml), and the result was 18 nm (volume weighting). Therefore, Compound 13 was considered to form micelles in water.
- Test Example 1 Drug Release in the absence of EHC and PARP inhibitor enzymes Compound 1, Compound 2, Compound 7, Compound 10, Compound 12, and Compound 13 were respectively added to PBS (phosphate buffered saline; pH 7.1). Dissolved at a concentration of 1 mg / ml and incubated at 37 ° C. EHC and PARP inhibitors released from the polymer compound were analyzed by HPLC and quantified using a standard curve. The ratio of the quantified amount to the total drug amount obtained from the drug content of the polymer compound is shown in FIG. 1-6.
- the polymer compounds of the present invention are hydrolyzed. Even in the absence of degrading enzyme, EHC and PARP inhibitor could be released simultaneously, and Compound 1, Compound 2, Compound 7, Compound 10, Compound 12, and Compound 13 could be released at almost the same rate. Depending on the bound PARP inhibitor, the release rate of EHC and PARP inhibitor may be altered.
- Test Example 2 Antitumor Activity Test of EHC and PARP Inhibitor BRCA1-Deficient Human Breast Cancer MX-1 Passed Subcutaneously in Mice is Blocked to a 2 mm Square Block and Transplanted into the Dorsal Subcutaneous Region of Nude Mice Using a Trocar did.
- the polymer compound (Compound 1) of the present invention Control Drug 1 (EHC-linked polyethylene glycol-polyglutamic acid block copolymer prepared by the method described in WO 2006/120914 pamphlet) and Control Drug 1 + Control drug 2 (Compound 11 of Reference Example 1) was intravenously administered 3 times every 7 days at the dose shown in Table 1. Each compound was used after being dissolved in a 5% glucose solution or physiological saline.
- the tumor start date and the tumor volume after the start of administration were measured with a caliper over time for the major axis (Lmm) and minor axis (Wmm) of the tumor, and calculated by the formula (LxW 2 ) / 2.
- the change of the relative tumor volume with respect to the tumor volume on the administration start day is shown in FIG.
- Compound 1 which is a polymer compound of the present invention is a combination of Control Drug 1 which is a polymer compound containing only EHC, and Control Drug 2 which is a polymer compound containing only a PARP inhibitor. In comparison, it shows that the same dose has a much stronger antitumor effect.
- Test Example 3 Anti-tumor activity test of EHC and PARP inhibitor Human pancreatic cancer BxPC-3 subcultured subcutaneously in mice was transplanted subcutaneously on the dorsal side of nude mice using a trocar in a block of about 2 mm square .
- the polymer derivatives of the present invention compound 1 and compound 13
- control drug 1 EHC-linked polyethylene glycol-polyglutamic acid block copolymer prepared by the method described in WO 2006/120914 pamphlet
- FIG. 8 shows the relative tumor volume ratio with respect to the tumor volume on the administration start day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyamides (AREA)
Abstract
Description
カンプトテシンは高い抗腫瘍効果を示し1960年代に抗癌剤として開発が進められたが、強い毒性として骨髄抑制と出血性膀胱炎が見られたために臨床試験が中止となった。
トポテカンは、代謝を経ずに抗腫瘍効果を発揮し、投与量の20-40%が腎排泄であるため副作用の下痢が軽度である。
イリノテカンはそれ自体でも抗腫瘍効果を有しているが、生体内でカルボキシルエステラーゼにより活性代謝物の7-エチル-10-ヒドロキシカンプトテシン(以下、EHCと記載)に代謝され、より強い抗腫瘍効果を発揮する。また、イリノテカン、EHCは、トポテカンよりも生物学的に活性であるラクトン型として血漿中に存在する割合が多く、更に半減期が長い特徴を有する。
PARP阻害剤は、PARPが酸化型NADを認識してDNAの修復を行う際、酸化型NADを競合的に阻害し薬理作用を発揮する。すなわち、PARPを阻害することにより腫瘍細胞のDNA一本鎖切断から、更に細胞の生存にとって重要な二本鎖DNA切断を生じさせ、腫瘍細胞を死に至らしめる。
しかしながら、カンプトテシン類と抗癌効果増強剤、例えば、PARP阻害剤とが同一分子に結合された高分子化合物は知られていない。
すなわち本発明は、以下の構成1)-12)を要旨とする。
7)抗癌効果増強剤がフェノール性水酸基を有するPARP阻害剤である前記1)-5)のいずれか一項に記載の高分子化合物。
8)抗癌効果増強剤がアルコール性水酸基を有するPARP阻害剤である前記3)-5)のいずれか一項に記載の高分子化合物。
9)PARP阻害剤が1H-ベンズイミダゾール-4-カルボキシアミド誘導体、オラパリブ誘導体、ルカパリブ誘導体、BMN673(5-Fluoro-8(S)-(4-fluorophenyl)-9(R)-(1-methyl-1H-1,2,4-triazol-5-yl)-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-3-one)誘導体からなる化合物群から選択される1種以上の化合物である前記6)に記載の高分子化合物。
11)PARP阻害剤が2-(4’-ヒドロキシメチルフェニル)-3,4,5,6-テトラヒドロ-1H-アゼピノ[5,4,3-cd]インドール-6-オンまたは4-[4-フルオロ-3-([1,4]ジアゼパン-1-カルボニル-4-ヒドロキシエチル)ベンジル]-2H-フタラジン-1-オンである前記6)、8)または9)のいずれか一項に記載の高分子化合物。
12)前記1)-11)のいずれか一項に記載の高分子化合物を薬効成分とする抗癌剤。
抗癌効果増強剤が分子内にフェノール性水酸基あるいは分子内に一級若しくは二級のアルコール性水酸基を有する場合には、該水酸基とブロック共重合体のポリグルタミン酸構造部分の側鎖カルボキシ基とをアスパラギン酸誘導体をリンカーとして結合させればよい。すなわち、抗癌効果増強剤の水酸基とアスパラギン酸誘導体のカルボキシ基とをエステル結合させ、残余のカルボキシ基をアミド化し、得られる化合物のアミノ基とブロック共重合体のポリグルタミン酸構造部分の側鎖カルボキシ基とをアミド結合により結合させればよい。該アスパラギン酸誘導体をリンカーとすることにより抗癌効果増強剤は非酵素的に遊離が容易となる。
式(8)及び式(9)で表される化合物自体は公知の化合物で、例えば、J.Med.Chem.,51,6581(2008)の記載に従い製造することができる。
式(10)-式(14)で表される化合物自体は公知の化合物で、例えば、国際公開第2000/042040号パンフレットの記載に従い製造することができる。
式(15)-式(17)で表される化合物自体は公知の化合物で、例えば、国際公開第2010/017055号パンフレットの記載に従い製造することができる。
ここで、CX-CYがC=C(二重結合)の場合はE配置が好ましい。なお、HODが抗癌効果増強剤を表す。
R8及びR9は共に水素原子が好ましい。
置換基を有していてもよい(C1-C40)アラルキル基における(C1-C40)アラルキル基としては、例えば、ベンジル基、ナフチルメチル基、フェネチル基、4-フェニルブチル基等が挙げられ、置換基としては、例えば、メチル基、エチル基、ニトロ基、塩素原子、臭素原子、ジメチルアミノ基等が挙げられる。
置換基を有していてもよい芳香族基としては、例えば、アニリン、ニトロアニリン、クロロアニリン、アミノフルオロベンゾニトリル、アミノナフタレン、アミノフラボン、アミノフルオレン等から導かれる基が挙げられる。
なお、各基における置換基の置換位置は置換可能であれば特に限定されず、置換数も特に限定されない。
前記R5と同様に、該(C3-C6)分岐若しくは環状アルキル基としては、例えば、イソプロピル基、イソブチル基、sec-ブチル基、tert-ブチル基、1-メチルブチル基、2-メチルブチル基、ネオペンチル基、シクロヘキシル基等が挙げられ、より好ましくはイソプロピル基、シクロへキシル基が挙げられ、該三級アミノ基で置換されていてもよい(C1-C5)分岐若しくは直鎖アルキル基としては、例えば、エチル基、ジメチルアミノプロピル基等が挙げられる。
脱保護前に該ブロック共重合体のポリグルタミン酸構造部分の末端アミノ基をアシル化しておいてもよい。
前記ポリエチレングリコール構造部分とポリグルタミン酸構造部分を有するブロック共重合体にEHC、抗癌効果増強剤若しくは抗癌効果増強剤が結合したアスパラギン酸誘導体等を結合させる。該結合方法は特に限定されるものではなく、先にEHCを結合させ、その後、該抗癌効果増強剤または抗癌効果増強剤が結合したアスパラギン酸誘導体等を結合させても、その逆順でも、同時に結合させてもよい。抗癌効果増強剤が結合したアスパラギン酸誘導体の製造方法の一例示を後記する。
高分子化合物と低分子化合物とは体内薬物動態挙動が大きく異なり、体内分布も大きく異なることが知られている。このことから本発明の高分子化合物は、低分子化合物の薬剤とは薬効発現特性及び副作用発現特性が異なることとなり、カンプトテシン誘導体と抗癌効果増強剤を用いた新しい治療方法を提供することができる。
国際公開2006/120914号パンフレットに記載された方法に準じた方法により調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体(分子量12000の片末端がメチル基、他方片末端がアミノプロピル基であるメトキシポリエチレングリコール構造部分と重合数が23のポリグルタミン酸構造部分(末端Nアセチル基)からなり、結合基がトリメチレン基であるブロック共重合体)462mg、EHC70mg及び2-(4-ヒドロキシフェニル)-1H-ベンズイミダゾール-4-カルボキシアミド(NU1085;式(7)で表される化合物)70mgをDMF8.5mlに溶解し、35℃にて15分攪拌した後、20℃にて1時間攪拌した。その後、DIPCI204μl、DMAP8.0mgを加えて、20℃にて21時間撹拌した。DIPCI102μlを追加し、更に4時間攪拌した。反応液をエタノール8.5ml、酢酸エチル8.5ml、ジイソプロピルエーテル68mlの混合溶液にゆっくり滴下し室温にて1時間攪拌し、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v))で洗浄した。得られた沈析物をアセトニトリル35ml及び水3.5mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、7.0ml)を加え攪拌し濾過した。得られた濾液中のアセトニトリルを減圧下留去し、次いで凍結乾燥することにより化合物1(530mg)を得た。
国際公開2006/120914号パンフレットに記載された方法に準じた方法により調製した実施例1記載のメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体453mg、EHC60mg及び2-(4’-ヒドロキシフェニル)-3,4,5,6-テトラヒドロ-1H-アゼピノ[5,4,3-cd]インドール-6-オン(PARP阻害剤2;式(12)で表される化合物)60mgをDMF8.4mlに溶解し、35℃にて25分攪拌した後、20℃にて1時間攪拌した。その後、DIPCI225μl、DMAP8.2mgを加えて、20℃にて22.5時間撹拌した。DIPCI49μlを追加し、更に3.25時間攪拌した。反応液をエタノール10ml、酢酸エチル3ml、ジイソプロピルエーテル80mlの混合溶液にゆっくり滴下し室温にて1時間攪拌し、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v))で洗浄した。得られた沈析物をアセトニトリル37ml及び水3.7mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、3.7ml)を加え攪拌し、濾過した。得られた濾液中のアセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物2(513mg)を得た。
N-(tert-ブトキシカルボニル)アスパラギン酸-4-ベンジルエステル5.0gと1-フェニルブチルアミン2.4mlをDMF30mlに溶解後、WSC塩酸塩3.8g、HOBt(N-ヒドロキシベンゾトリアゾール)2.2gを加え、室温にて5時間攪拌した。反応液に水を加え、酢酸エチルにて抽出し、飽和炭酸水素ナトリウム水溶液で洗浄した。硫酸マグネシウムで乾燥後、減圧下、酢酸エチルを留去し、真空乾燥して化合物3を7.2g得た。
MS:m/z 477(M+Na)+ C26H34N2O5(M+Na)+としての計算値 477
合成例1で得られた7.2gの化合物3を酢酸エチル30mlに溶解し、5%パラジウム炭素(水分含量50%)2.8gを加えた後、系内を水素置換し、水素雰囲気下、室温にて一夜攪拌した。5%パラジウム炭素を濾過し酢酸エチルで洗浄後、濾液と洗浄液を合わせて減圧下、酢酸エチルを留去し、真空乾燥して化合物4を5.4g得た。
MS:m/z 387(M+Na)+ C19H28N2O5(M+Na)+としての計算値 387
合成例2で得られた1.11gの化合物4と2-(4’-ヒドロキシメチルフェニル)-3,4,5,6-テトラヒドロ-1H-アゼピノ[5,4,3-cd]インドール-6-オン(PARP阻害剤3;式(14)で表される化合物)745mgをDMF13mlに溶解後、DIPCI743μl、DMAP31mgを加えて室温にて18時間攪拌した。反応液に水を加え、酢酸エチルにて抽出し、飽和炭酸水素ナトリウム水溶液、飽和塩化ナトリウム水溶液の順で洗浄した。硫酸ナトリウムで乾燥後、減圧下、酢酸エチルを留去した。得られた油状物をシリカゲルカラムクロマトグラフィー(CHCl3/MeOH)にて精製し、化合物5を2.12g得た。
MS:m/z 639(M+H)+ C37H43N4O6(M+H)+としての計算値 639
合成例3で得られた2.06gの化合物5に、4N-HCl酢酸エチル溶液20mlを加え、室温にて3時間攪拌した。反応終了後減圧下、酢酸エチルを留去して化合物6を2.36g得た。
MS:m/z 539(M+H)+ C32H35N4O4(M+H)+としての計算値 539
国際公開2006/120914号パンフレットに記載された方法に準じた方法により調製した実施例1記載のメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体403mgをDMF7.5mlに溶解し、35℃にて30分攪拌した後、25℃にて1時間攪拌した。その後、EHC60mg及びDIPCI44μl、DMAP7.3mgを加え、25℃にて4.5時間撹拌した。合成例4で得られた190mgの化合物6、N,N-ジイソプロピルエチルアミン63μl及びDIPCI130μlを加え、更に18.5時間攪拌した。反応液をエタノール15ml、酢酸エチル15ml、ジイソプロピルエーテル120mlの混合溶液にゆっくり滴下し室温にて1時間攪拌し、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v))で洗浄した。得られた沈析物をアセトニトリル38ml及び水3.8mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、7.6ml)を加え攪拌し、濾過した。得られた濾液中のアセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物7を510mg得た。
合成例2で得られた1.5gの化合物4と4-[4-フルオロ-3-([1,4]ジアゼパン-1-カルボニル-4-ヒドロキシエチル)ベンジル]-2H-フタラジン-1-オン(PARP阻害剤4;式(8)で表される化合物)2.1gをDMF8.2mlに溶解後、DIPCI1.3ml、DMAP50mgを加えて、室温にて20時間攪拌した。反応液に水を加え、酢酸エチルにて抽出し、飽和炭酸水素ナトリウム水溶液、飽和塩化ナトリウム水溶液の順で洗浄した。硫酸マグネシウムで乾燥後、減圧下、酢酸エチルを留去した。得られた油状物をシリカゲルカラムクロマトグラフィー(CHCl3/MeOH)にて精製し、化合物8を2.6g得た。
MS:m/z 771(M+H)+ C42H51FN6O7(M+H)+としての計算値 771
合成例5で得られた1.6gの化合物8を酢酸エチル5.1mlに溶解後、4N-HCl酢酸エチル溶液5.1mlを加え、室温にて1時間攪拌した。反応終了後減圧下、酢酸エチルを留去して化合物9を1.4g得た。
MS:m/z 671(M+H)+ C38H45FN6O5(M+H)+としての計算値 671
国際公開2006/120914号パンフレットに記載された方法に準じた方法により調製した実施例1記載のメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体518mgをDMF8.0mlに溶解し、35℃にて15分攪拌した後、25℃にて1時間攪拌した。その後、EHC100mg及びDIPCI60μl、DMAP9.4mgを加え、25℃にて6時間撹拌した。合成例6で得られた149mgの化合物9、N,N-ジイソプロピルエチルアミン38μl及びDIPCI180μlを加え、更に18時間攪拌した。反応液をエタノール10ml、酢酸エチル10ml、ジイソプロピルエーテル80mlの混合溶液にゆっくり滴下し室温にて1時間攪拌し、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v))で洗浄した。得られた沈析物をアセトニトリル40ml及び水4.0mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、8.0ml)を加え攪拌し濾過した。得られた濾液中のアセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物10を650mg得た。
国際公開2006/120914号パンフレットに記載された方法に準じた方法により調製した実施例1記載のメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体1.97gと400mgのNU1085をDMF35mlに溶解し、35℃にて20分攪拌した後、20℃にて1時間攪拌した。その後、DIPCI856μl、DMAP35mgを加えて、20℃にて19時間撹拌した。DIPCI102μlを追加し、更に3時間攪拌した。反応液をエタノール35ml、酢酸エチル35ml、ジイソプロピルエーテル280mlの混合溶液にゆっくり滴下し室温にて2時間攪拌し、沈析物を濾取してエタノール/ジイソプロピルエーテル(1/4(v/v))で洗浄した。得られた沈析物をアセトニトリル40ml及び水4mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、12ml)を加え攪拌し濾過した。得られた濾液のアセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物11を1.96g得た。
国際公開2006/120914号パンフレットに記載された方法に準じた方法により調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体(分子量5000の片末端がメチル基、他方片末端がアミノプロピル基であるポリエチレングリコール構造部分と重合数が10のポリグルタミン酸構造部分(末端アセチル基)からなるブロック共重合体)620mg、EHC100mgおよび2-(4-ヒドロキシフェニル)ベンズイミダゾール-1H-4-カルボキシアミド(NU1085)100mgをDMF12mlに溶解し、35℃にて35分攪拌した後、20℃にて1時間攪拌した。その後、DIPCI307μl、DMAP12mgを加えて、20℃にて18時間撹拌した。DIPCI154μlを追加し、更に4時間攪拌した。反応液を酢酸エチル36ml、ジイソプロピルエーテル144mlの混合溶液にゆっくり滴下し室温にて1時間攪拌し、沈析物を濾取して酢酸エチルで洗浄した。得られた沈析物をアセトニトリル8.0ml及び水2.0mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、4.0ml)を加え攪拌し、濾過した。得られた濾液中のアセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物12(750mg)を得た。
国際公開2006/120914号パンフレットに記載された方法により調製したメトキシポリエチレングリコール-ポリグルタミン酸ブロック共重合体(分子量5000の片末端がメチル基、他方片末端がアミノプロピル基であるポリエチレングリコール構造部分と重合数が10のポリグルタミン酸構造部分からなるブロック共重合体(末端Nアセチル基)164mgをDMF5.0mlに溶解し、35℃にて15分攪拌した後、25℃にて1時間攪拌した。その後、EHC34mgおよびDIPCI20μl、DMAP3.2mgを加え、25℃にて6時間撹拌した。合成例6で得られた化合物9を50mg、N,N-ジイソプロピルエチルアミン14.6μlおよびDIPCI61μlを加え、更に20時間攪拌した。反応液を酢酸エチル15ml、ジイソプロピルエーテル60mlの混合溶液にゆっくり滴下し室温にて3時間攪拌し、沈析物を濾取して酢酸エチルで洗浄した。得られた沈析物をアセトニトリル8.0ml及び水2.0mlに溶解後、イオン交換樹脂(ダウケミカル製ダウエックス50(H+)、2.0ml)を加え攪拌し濾過した。得られた濾液中のアセトニトリルを減圧下留去し、次いで、凍結乾燥することにより化合物13を220mg得た。
化合物1、化合物2、化合物7、化合物10、化合物12及び化合物13をそれぞれPBS(リン酸緩衝生理食塩水;pH7.1)に1mg/mlの濃度で溶解し37℃にてインキュベートした。該高分子化合物より放出されたEHC及びPARP阻害剤をHPLCにて分析し標準曲線を用いて定量した。高分子化合物の薬剤含有量から求めた全薬剤量に対する定量された量の割合を図1-6に示した。
マウス皮下で継代しているBRCA1欠損ヒト乳癌MX-1を約2mm角のブロックにし套管針を用いてヌードマウスの背側部皮下に移植した。腫瘍移植後18日目から本発明の高分子化合物(化合物1)、対照薬1(国際公開第2006/120914号パンフレット記載の方法で作成したEHC結合ポリエチレングリコール-ポリグルタミン酸ブロック共重合体)及び対照薬1+対照薬2(参考例1の化合物11)を表1に示す投与量で静脈内に7日おきに3回投与した。なお、各化合物は5%ブドウ糖溶液若しくは生理食塩水で溶解して使用した。
Claims (12)
- 下記一般式(1)で表される高分子化合物。
- R1がメチル基またはエチル基、Aがエチレン基またはトリメチレン基、R2がアセチル基またはプロピオニル基、R6、R7が共にシクロヘキシル基またはイソプロピル基であり、d+e+f+g+hに対するdの割合が5-40%、eの割合が5-80%、fの割合が0-60%、gの割合が5-40%、hの割合が0-30%である請求項1に記載の高分子化合物。
- R8、R9がともに水素原子であり、CX-CYはCH-CHであり、R10がフェニルブチル基である請求項3または4に記載の高分子化合物。
- 前記抗癌効果増強剤がPARP阻害剤である請求項1-5のいずれか一項に記載の高分子化合物。
- 前記抗癌効果増強剤がフェノール性水酸基を有するPARP阻害剤である請求項1-5のいずれか一項に記載の高分子化合物。
- 前記抗癌効果増強剤がアルコール性水酸基を有するPARP阻害剤である請求項3-5のいずれか一項に記載の高分子化合物。
- 前記PARP阻害剤が1H-ベンズイミダゾ-ル-4-カルボキシアミド誘導体、オラパリブ誘導体、ルカパリブ誘導体、BMN673誘導体からなる化合物群から選択される1種以上の化合物である請求項6に記載の高分子化合物。
- 前記PARP阻害剤が2-(4-ヒドロキシフェニル)-1H-ベンズイミダゾール-4-カルボキシアミドまたは2-(4’-ヒドロキシフェニル)-3,4,5,6-テトラヒドロ-1H-アゼピノ[5,4,3-cd]インドール-6-オンである請求項6、7または9に記載の高分子化合物。
- 前記PARP阻害剤が2-(4’-ヒドロキシメチルフェニル)-3,4,5,6-テトラヒドロ-1H-アゼピノ[5,4,3-cd]インドール-6-オンまたは4-[4-フルオロ-3-([1,4]ジアゼパン-1-カルボニル-4-ヒドロキシエチル)ベンジル]-2H-フタラジン-1-オンである請求項6、8または9のいずれか一項に記載の高分子化合物。
- 請求項1-11のいずれか一項に記載の高分子化合物を薬効成分とする抗癌剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014545671A JP6223995B2 (ja) | 2012-11-08 | 2013-10-31 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
EP13853624.8A EP2918292B1 (en) | 2012-11-08 | 2013-10-31 | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
US14/440,090 US9855261B2 (en) | 2012-11-08 | 2013-10-31 | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012246037 | 2012-11-08 | ||
JP2012-246037 | 2012-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014073447A1 true WO2014073447A1 (ja) | 2014-05-15 |
Family
ID=50684555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/079551 WO2014073447A1 (ja) | 2012-11-08 | 2013-10-31 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9855261B2 (ja) |
EP (1) | EP2918292B1 (ja) |
JP (1) | JP6223995B2 (ja) |
TW (1) | TWI598108B (ja) |
WO (1) | WO2014073447A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015125640A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
WO2017150256A1 (ja) * | 2016-03-01 | 2017-09-08 | 日本化薬株式会社 | カンプトテシン類高分子誘導体を含有する医薬製剤 |
WO2018025657A1 (ja) * | 2016-07-30 | 2018-02-08 | 日本化薬株式会社 | 新規な高分子誘導体、及びそれらを用いた新規な高分子誘導体イメージングプローブ |
JP2018520140A (ja) * | 2015-06-25 | 2018-07-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
JP2018521072A (ja) * | 2015-07-23 | 2018-08-02 | アンスティテュ・キュリInstitut Curie | 癌を処置するためのDbait分子とPARPインヒビターとの組合せの使用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074409A (zh) * | 2016-06-13 | 2016-11-09 | 佛山市腾瑞医药科技有限公司 | 一种奥拉帕尼制剂及其应用 |
CN109485845B (zh) * | 2018-09-13 | 2021-04-20 | 天津大学 | 一种疏水改性聚谷氨酸的制备方法及其促进海藻糖载入细胞的应用 |
CN114053276B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042040A1 (en) | 1999-01-11 | 2000-07-20 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
WO2006120914A1 (ja) | 2005-05-11 | 2006-11-16 | Nippon Kayaku Kabushiki Kaisha | シチジン系代謝拮抗剤の高分子誘導体 |
WO2009116509A1 (ja) * | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
WO2009142328A1 (ja) * | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | カンプトテシン高分子誘導体及びその用途 |
WO2010017055A2 (en) | 2008-08-06 | 2010-02-11 | Lead Therapeutics, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
JP2010519305A (ja) | 2007-02-26 | 2010-06-03 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | 併用薬物送達のためのポリマー性ミセル |
WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
WO2012067138A1 (ja) * | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
-
2013
- 2013-10-31 EP EP13853624.8A patent/EP2918292B1/en active Active
- 2013-10-31 JP JP2014545671A patent/JP6223995B2/ja active Active
- 2013-10-31 WO PCT/JP2013/079551 patent/WO2014073447A1/ja active Application Filing
- 2013-10-31 US US14/440,090 patent/US9855261B2/en active Active
- 2013-11-07 TW TW102140567A patent/TWI598108B/zh not_active IP Right Cessation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042040A1 (en) | 1999-01-11 | 2000-07-20 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
WO2006120914A1 (ja) | 2005-05-11 | 2006-11-16 | Nippon Kayaku Kabushiki Kaisha | シチジン系代謝拮抗剤の高分子誘導体 |
JP2010519305A (ja) | 2007-02-26 | 2010-06-03 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | 併用薬物送達のためのポリマー性ミセル |
WO2009116509A1 (ja) * | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
WO2009142328A1 (ja) * | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | カンプトテシン高分子誘導体及びその用途 |
WO2010017055A2 (en) | 2008-08-06 | 2010-02-11 | Lead Therapeutics, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
WO2012067138A1 (ja) * | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
Non-Patent Citations (5)
Title |
---|
BAE Y, KATAOKA K ET AL.: "Intelligent polymeric micelles from functional poly(ethylene glycol)- poly(amino acid) block copolymers.", ADVANCED DRUG DELIVERY REVIEWS, vol. 61, no. 10, 2009, pages 768 - 784, XP026234407 * |
J. MED. CHEM., vol. 43, 2000, pages 4084 |
J. MED. CHEM., vol. 51, 2008, pages 6581 |
SOHAIL, HONEAH ET AL.: "PARP inhibitor ABT-888 as potentiating agent for topoisomerase inhibitor SN-38, Graduate School", NEW BRUNSWICK ELECTRONIC THESES AND DISSERTATIONS, 2009, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, pages II, XP055249798 * |
YOUNSOO BAE; KAZUNORI KATAOKA, ADV. DRUG DELIV.REV., vol. 61, 2009, pages 768 - 784 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015125640A1 (ja) * | 2014-02-19 | 2015-08-27 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
JPWO2015125640A1 (ja) * | 2014-02-19 | 2017-03-30 | 日本化薬株式会社 | カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途 |
JP2018520140A (ja) * | 2015-06-25 | 2018-07-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
JP2018521072A (ja) * | 2015-07-23 | 2018-08-02 | アンスティテュ・キュリInstitut Curie | 癌を処置するためのDbait分子とPARPインヒビターとの組合せの使用 |
WO2017150256A1 (ja) * | 2016-03-01 | 2017-09-08 | 日本化薬株式会社 | カンプトテシン類高分子誘導体を含有する医薬製剤 |
US20190046653A1 (en) * | 2016-03-01 | 2019-02-14 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical Preparation Containing Camptothecin-Based Polymeric Derivative |
WO2018025657A1 (ja) * | 2016-07-30 | 2018-02-08 | 日本化薬株式会社 | 新規な高分子誘導体、及びそれらを用いた新規な高分子誘導体イメージングプローブ |
JPWO2018025657A1 (ja) * | 2016-07-30 | 2019-06-27 | 日本化薬株式会社 | 新規な高分子誘導体、及びそれらを用いた新規な高分子誘導体イメージングプローブ |
US20190307905A1 (en) * | 2016-07-30 | 2019-10-10 | Nippon Kayaku Kabushiki Kaisha | Novel Polymer Derivatives, And Novel Polymer Derivative Imaging Probe Using Same |
US10869937B2 (en) | 2016-07-30 | 2020-12-22 | Nippon Kayaku Kabushiki Kaisha | Polymer derivatives, and novel polymer derivative imaging probe using same |
Also Published As
Publication number | Publication date |
---|---|
EP2918292A4 (en) | 2016-06-08 |
JPWO2014073447A1 (ja) | 2016-09-08 |
TW201427693A (zh) | 2014-07-16 |
US9855261B2 (en) | 2018-01-02 |
TWI598108B (zh) | 2017-09-11 |
EP2918292B1 (en) | 2019-12-11 |
JP6223995B2 (ja) | 2017-11-01 |
EP2918292A1 (en) | 2015-09-16 |
US20150290185A1 (en) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6223995B2 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
ES2488841T3 (es) | Derivados de alto peso molecular de camptotecinas | |
US8808749B2 (en) | Polymer conjugate of bioactive substance having hydroxy group | |
US8323669B2 (en) | Polymer conjugate of taxane | |
US8920788B2 (en) | High-molecular weight conjugate of physiologically active substances | |
JP5856069B2 (ja) | 新規なシチジン系代謝拮抗剤の高分子誘導体 | |
EP2042195A1 (en) | Polymer conjugate of combretastatin | |
WO2018028589A1 (zh) | 一种多聚结合物及其制备方法,以及包含该多聚结合物的药物组合物及其用途 | |
JP6851977B2 (ja) | マクロライド系免疫抑制剤の高分子誘導体 | |
US20220395525A1 (en) | Therapeutic dendrimer | |
JP6830907B2 (ja) | マクロライド系免疫抑制剤の高分子誘導体 | |
EP2854864A1 (en) | Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13853624 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014545671 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013853624 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14440090 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |